Today’s Short Interest Alert: Is Buying Tandem Diabetes Care Incorporated (NASDAQ:TNDM), Having Higher Short Interest a Winning Strategy?

November 17, 2016 - By Richard Conner   ·   0 Comments

Today's Short Interest Alert: Is Buying Tandem Diabetes Care Incorporated (NASDAQ:TNDM), Having Higher Short Interest a Winning Strategy?

The stock of Tandem Diabetes Care Incorporated (NASDAQ:TNDM) registered an increase of 3.91% in short interest. TNDM’s total short interest was 1.68 million shares in November as published by FINRA. Its up 3.91% from 1.61M shares, reported previously. With 129,100 shares average volume, it will take short sellers 13 days to cover their TNDM’s short positions. The short interest to Tandem Diabetes Care Incorporated’s float is 8.99%. About 866,097 shares traded hands or 104.71% up from the average. Tandem Diabetes Care Inc (NASDAQ:TNDM) has declined 78.90% since April 15, 2016 and is downtrending. It has underperformed by 83.53% the S&P500.

Tandem Diabetes Care, Inc. is a medical device company. The company has a market cap of $72.59 million. The Firm is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. It currently has negative earnings. The Firm makes and sells three insulin pump products, which include t:slim Insulin Delivery System , t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Insitutional Activity: The institutional sentiment decreased to 1.02 in Q2 2016. Its down 0.26, from 1.28 in 2016Q1. The ratio dived, as 18 funds sold all Tandem Diabetes Care Inc shares owned while 24 reduced positions. 9 funds bought stakes while 34 increased positions. They now own 17.85 million shares or 6.33% less from 19.06 million shares in 2016Q1.
D E Shaw And Co last reported 67,179 shares in the company. Bogle Investment Mngmt L P De owns 122,811 shares or 0.06% of their US portfolio. Blackrock Fund Advsr accumulated 477,327 shares or 0% of the stock. Cubist Systematic Strategies Limited Liability, a Connecticut-based fund reported 3,834 shares. Moreover, Blackrock Inc has 0% invested in Tandem Diabetes Care Inc (NASDAQ:TNDM) for 1,269 shares. Manufacturers Life Insurance The has 0% invested in the company for 4,864 shares. American International Grp Inc Inc accumulated 10,707 shares or 0% of the stock. Alliancebernstein Limited Partnership has invested 0% of its portfolio in Tandem Diabetes Care Inc (NASDAQ:TNDM). Morgan Stanley has 719 shares for 0% of their US portfolio. Endurant Capital Mgmt L P holds 230,671 shares or 0.58% of its portfolio. The Texas-based Tpg Group Hldgs (Sbs) Advsrs has invested 0.21% in Tandem Diabetes Care Inc (NASDAQ:TNDM). Vanguard Gp Inc has 0% invested in the company for 738,878 shares. Da Davidson And has 1,000 shares for 0% of their US portfolio. Tower Research Ltd (Trc) last reported 0% of its portfolio in the stock. Moreover, Amer Century Companies has 0% invested in Tandem Diabetes Care Inc (NASDAQ:TNDM) for 246,224 shares.

Tandem Diabetes Care Inc (NASDAQ:TNDM) Ratings Coverage

Out of 9 analysts covering Tandem Diabetes Care (NASDAQ:TNDM), 3 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 33% are positive. Tandem Diabetes Care has been the topic of 17 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The rating was downgraded by Bank of America to “Neutral” on Thursday, January 14. Zacks upgraded Tandem Diabetes Care Inc (NASDAQ:TNDM) rating on Saturday, August 22. Zacks has “Hold” rating and $13 price target. The stock has “Buy” rating given by Zacks on Friday, August 28. Deutsche Bank maintained Tandem Diabetes Care Inc (NASDAQ:TNDM) rating on Monday, August 10. Deutsche Bank has “Buy” rating and $19.0 price target. The firm has “Neutral” rating given on Wednesday, November 2 by Robert W. Baird. The company was downgraded on Wednesday, November 2 by Feltl & Co. Zacks upgraded Tandem Diabetes Care Inc (NASDAQ:TNDM) rating on Wednesday, August 5. Zacks has “Sell” rating and $15 price target. The company was downgraded on Thursday, March 24 by Bank of America. The company was maintained on Wednesday, November 2 by Wedbush. The company was downgraded on Thursday, November 3 by PiperJaffray.

TNDM Company Profile

Tandem Diabetes Care, Inc., incorporated on January 7, 2008, is a medical device company. The Firm is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Firm makes and sells over three insulin pump products in the United States that are designed to address insulin-dependent diabetes market, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4). The Company’s technology platform features Micro-Delivery Technology, a miniaturized pumping mechanism, which draws insulin from a flexible bag within the pump’s cartridge rather than relying on a syringe and plunger mechanism. The Firm also features a software, which is a vivid color touch screen and a micro- universal serial bus (USB) connection that supports both a rechargeable battery and uploads to t:connect Diabetes Management Application (t:connect), its custom cloud data management application that provides display therapy management data from the pump and supported blood glucose meters.

More recent Tandem Diabetes Care Inc (NASDAQ:TNDM) news were published by: Businesswire.com which released: “NIH-funded International Diabetes Closed Loop (IDCL) Trial to Combine …” on November 10, 2016. Also Fool.com published the news titled: “Why Insulet Corporation and Tandem Diabetes Care Both Tanked Today” on May 03, 2016. Businesswire.com‘s news article titled: “Tandem Diabetes Care Reports Third Quarter 2016 Financial Results” with publication date: November 01, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Richard Conner


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>